These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34397109)

  • 61. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
    Hillmen P; Muus P; Röth A; Elebute MO; Risitano AM; Schrezenmeier H; Szer J; Browne P; Maciejewski JP; Schubert J; Urbano-Ispizua A; de Castro C; Socié G; Brodsky RA
    Br J Haematol; 2013 Jul; 162(1):62-73. PubMed ID: 23617322
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
    Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
    Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.
    Röth A; Bommer M; Hüttmann A; Herich-Terhürne D; Kuklik N; Rekowski J; Lenz V; Schrezenmeier H; Dührsen U
    Blood Adv; 2018 Oct; 2(19):2543-2549. PubMed ID: 30291112
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term Use of Eculizumab for Prolonged Hemolysis Following a Delayed Hemolytic Transfusion Reaction in Pediatric Sickle Cell: A Case Report.
    Noda C; Sisler I
    J Pediatr Pharmacol Ther; 2022; 27(6):569-572. PubMed ID: 36988996
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria requiring transfusions 14 years after a diagnosis in childhood.
    Ueda T; Hayakawa J; Yamanishi M; Maeda M; Fukunaga Y
    J Nippon Med Sch; 2013; 80(2):155-9. PubMed ID: 23657069
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab.
    Choo SZ; Brown F
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():4-6. PubMed ID: 28176471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.
    Vidler JB; Gardner K; Amenyah K; Mijovic A; Thein SL
    Br J Haematol; 2015 Jun; 169(5):746-53. PubMed ID: 25753472
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
    Pirenne F; Bartolucci P; Habibi A
    Transfus Clin Biol; 2017 Sep; 24(3):227-231. PubMed ID: 28669521
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
    Kawano H; Minagawa K; Wakahashi K; Kawano Y; Sada A; Matsui T; Hirano H; Shiomi H; Ku Y; Katayama Y
    Intern Med; 2012; 51(18):2613-6. PubMed ID: 22989836
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
    Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
    Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Successful pregnancy and delivery achieved with eculizumab administration initiated after a preceding missed abortion in a patient with paroxysmal nocturnal hemoglobinuria].
    Tsutsui M; Gotoh A; Komatsu N
    Rinsho Ketsueki; 2019; 60(4):281-285. PubMed ID: 31068556
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hematopoietic stem cell transplantation for people with ß-thalassaemia major.
    Jagannath VA; Fedorowicz Z; Al Hajeri A; Sharma A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008708. PubMed ID: 27900772
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fatal Delayed Haemolytic Transfusion Reaction and Hyperhaemolysis Syndrome in a Pregnant Woman with Sickle Cell Anaemia.
    Asnawi AW; Sathar J; Mohamed R; Deraman R; Kumaran S; Hamid SS; Zakaria MZ
    Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):251-3. PubMed ID: 27408406
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria.
    Kim JS; Lee JW; Kim BK; Lee JH; Chung J
    Korean J Hematol; 2010 Dec; 45(4):269-74. PubMed ID: 21253430
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
    Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Ozawa K; Omine M
    Int J Hematol; 2013 Oct; 98(4):406-16. PubMed ID: 23934275
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.
    Chua J; Paizis K; He SZ; Mount P
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():18-22. PubMed ID: 28176472
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
    Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
    Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
    Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Health related quality of life among children with transfusion dependent β-thalassaemia major and haemoglobin E β-thalassaemia in Sri Lanka: a case control study.
    Mettananda S; Pathiraja H; Peiris R; Bandara D; de Silva U; Mettananda C; Premawardhena A
    Health Qual Life Outcomes; 2019 Aug; 17(1):137. PubMed ID: 31395066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.